Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
11 Agosto 2023 - 5:01PM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced the grant of inducement
awards to three new employees. The Compensation Committee of the
Board of Directors of Marinus approved the grant of non-qualified
stock options to purchase an aggregate of 43,050 shares of its
common stock (the “Common Stock”) as inducements material to the
employees entering into employment with the Company in accordance
with Nasdaq Listing Rule 5635(c)(4).
These stock option grants have an exercise price of $8.91 per
share, which is equal to the closing price of the Common Stock on
August 8, 2023 (date of grant for such stock options). All of the
stock options will vest and become exercisable as to 25% of the
underlying shares on the one-year anniversary of the applicable
employee’s start date of employment, and will vest and become
exercisable as to the remaining 75% of the underlying shares of
Common Stock in 36 equal monthly installments thereafter on each
monthly anniversary, subject to the applicable employee’s continued
employment with Marinus on such vesting dates. The stock options
were granted as an inducement material to each of the employees
entering into employment with Marinus in accordance with Nasdaq
Listing Rule 5635(c)(4), and are subject to the terms and
conditions of the applicable award agreement covering such
grant.
About Marinus Pharmaceuticals
Marinus is a commercial stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company’s commercial product, ZTALMY® (ganaxolone)
oral suspension CV, has been approved by the U.S. FDA for the
treatment of seizures associated with CDKL5 deficiency disorder in
patients two years of age and older. The potential of ganaxolone is
also being studied in other rare seizure disorders, including in
Phase 3 trials in tuberous sclerosis complex and refractory status
epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor
modulator that acts on a well-characterized target in the brain
known to have anti-seizure effects. It is being developed in IV and
oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information visit www.marinuspharma.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Marinus, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Words such as “may”, “will”, “expect”, “anticipate”, “estimate”,
“intend”, “believe”, and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this press release involve
substantial risks and uncertainties that could cause our clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Marinus undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of the
Company in general, see filings Marinus has made with the
Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230811617912/en/
Company: Molly Cameron Director, Corporate Communications
& Investor Relations Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024